Successful outcomes following immunotherapies for the treatment of cancer have been linked to the generation of effector CD8+ and CD4+ T-cell responses, followed by the establishment of memory T-cell population capable of combatting re-emergence of the tumor [25]. This evidence concerns the gene CD8A and cancer.